Study objective. To investigate the feasibility of routine monitoring for workplace antineoplastic agent contamination in the Alberta Cancer Board (ACB) pharmacy practice environment.
Setting. The ACB in the Canadian province of Alberta, which includes two public tertiary centres and 17 associated community satellite sites based around the province in existing hospitals. Methods. Obtained organizational support and input prior to launching the feasibility study (Phase I). Samples were analysed for a common cytotoxic agent - cyclophosphamide. Surfaces chosen were within the biological safety cabinets, workplace counter tops and on external surfaces of vials provided by manufacturers. Blank samples and known contaminated controls were included in Phase I to reconfirm the methodology in a previously published study.1 Feasibility aspects of logistics and financial expenses were examined. A second phase (Phase II) was completed to test other areas of the pharmacy and vials, with blank samples included to reconfirm previously mentioned methodology.
Results. The results determined that the samples tested were below acceptable detection limits with the exception of the known contaminated sample (Phase I) and exterior surfaces of vials (Phase II).
Conclusion. This project has increased staff awareness of the sources for antineoplastic agent workplace contamination. Some practice changes were instituted during the project itself. Logistics and expenses were realistic for routine monitoring to be adopted.
Connor TH, Anderson RW, Sessink PJ, et al.Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. AM J Health Syst Pharm1999; 56: 1427-1432.
2.
Falck K, Grohn P, Sorsa M, et al.Mutagenicity in urine of nurses handling cytostatic drugs. Lancet1979; 1: 1250-1251.
3.
American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic drugs in hospitals. Am J Hosp Pharm1985; 42: 131-137.
4.
Recommendations for handling cytotoxic agents. Providence, RI: National Study Commission on Cytotoxic Exposure, 1987.
5.
Cancer Chemotherapy guidelines: recommendations for nursing practice in the acute care setting. Pittsburgh, PA: Oncology Nursing Society, 1982.
6.
US Department of Labor guidelines for cytotoxic drugs. Washington, DC: Office of Occupational Medicine, US. Occupational Health and Safety Administration, 1986; publication no. 8-1.1.
7.
American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm1990; 47: 1033-1049.
8.
OSHA Instructions TED 1.15. Directorate of technical support. Controlling occupational exposure to hazardous drugs. Washington, DC: US Occupational Health and Safety Administration, 1995.
9.
Guidelines for the handling and disposal of hazardous pharmaceuticals (including cytotoxic drugs). Ottawa, Ontario, Canada: Canadian Society of Hospital Pharmacists, 1993.
10.
BC Cancer Agency, Division of Pharmacy, Aseptic and Safe Preparation of Cytotoxic Drugs, August 1995.
11.
Power LA, Anderson RW, Cortopassi R, et al.Update on safe handling of hazardous drugs: the advice of experts. Am J Hosp Pharm1990; 47: 1050-1060.
12.
National Institute for Occupational Safety and Health, Preventing Occupational Exposure to Antineoplastic and other Hazardous Drugs in Healthcare Settings. Publication Copy on NIOSH website. Retrieved September 2004, from http://www.cdc.gov/niosh, No. 2004-165.
Peters BG, Wilson AL, Lunik MC, Cataldo BK.Certification program in antineoplastic drug preparation for pharmacy technicians and pharmacists. Am J Hosp Pharm1994; 51: 1902-1906.
15.
Canadian Society of Hospital Pharmacists. Guidelines for the Preparation of Sterile Products in Pharmacies, 1996.
16.
Chambers C, Douchet L, Dobish R.Training manual for the preparation of parenteral cytotoxic admixtures. Alberta Cancer Board Pharmacy. 7; 5-5:2002.
17.
Exposure Control B.V., PO Box 467, 6600 AL Wijchen, the Netherlands. Instructions of Use, Cyto Wipe Kit, Retrieved from http://www.exposurecontrol.nl, 27 February 2003.
18.
Opiolka S, Molter W, Goldschmidt R, et al. Umgang mit Zytostatika. Krankenhaus Technik 1998; Mar: 56 -58.
19.
Sessink P. Exposure Control B.V., PO Box 467, 6600 AL Wijchen, the Netherlands, e-mail correspondence, 6 September, 2003.
20.
SessinkP.ExposureControlB.V., POBox467,6600ALWijchen, the Netherlands, e-mail correspondence, 11 March, 2004.
21.
Connor TH, Sessink PJM, Harrison BR, et al.Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: results of three studies. Am J Hosp Pharm2005; 62: 475-484.
